Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patient...

Full description

Bibliographic Details
Main Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Thymoma
Immunotherapy
Avelumab
Immune-related adverse events
Immunosuppressive therapy
Anti-PD-L1
Online Access:http://link.springer.com/article/10.1186/s40425-019-0723-9

Internet

http://link.springer.com/article/10.1186/s40425-019-0723-9

Similar Items